Ge Long Hui·2026-01-20 11:31Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of HRS-2141 tablets for type 2 diabetes [1] Group 1: Company Announcement - Jiangsu Heng Rui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Medicine Co., Ltd., has been granted a clinical trial approval notice for HRS-2141 tablets (I) and (II) [1] - The approval allows the company to conduct clinical trials for the drug targeting type 2 diabetes [1] - The acceptance numbers for the clinical trial applications are CXHL2501153 and CXHL2501154 [1] Group 2: Regulatory Details - The approval conclusion states that HRS-2141 tablets (I) and (II) meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] - The clinical trials are set to commence following the approval, which was granted based on a review conducted on October 21, 2025 [1]